The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
10.22465/kjuo.2022.20.1.1
- Author:
Jae Young JOUNG
1
;
Sung Han KIM
Author Information
1. Department of Urology, Center for Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea
- Publication Type:Review Article
- From:Korean Journal of Urological Oncology
2022;20(1):1-11
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Poly (ADP-ribose) polymerase inhibitors (PARP inhibitor) is a new targeted drug for metastatic prostate cancer in which the patient has a mutation on homologous repair gene including BRCA1/2 gene. This drug was the first gene-based targeted agent in prostate cancer and there were more than 5 available drugs for PARP inhibitors. Only 4 were approved for clinical use for patients with cancer from the U.S. Food and Drug Administration. This review article deals with the overview of the PARP inhibitors and their use in future research and clinical fields.
